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Arginine Vasopressin Enhances Sympathetic Constriction
Through the V1 Vasopressin Receptor in
Human Saphenous Vein
Pascual Medina, PhD; Antonio Acun˜a, BSc; Juan B. Martı´nez-Leo´n, MD; Eduardo Otero, MD;
Jose´ M. Vila, PhD; Martı´n Aldasoro, MD; Salvador Lluch, MD
Background—Arginine vasopressin (AVP) not only acts directly on blood vessels through V1 receptor stimulation but also may
modulate adrenergic-mediated responses in animal experiments in vivo and in vitro. The aim of the present study was to
investigate whether AVP can contribute to an abnormal adrenergic constrictor response of human saphenous veins.
Methods and Results—Saphenous vein rings were obtained from 32 patients undergoing coronary artery bypass surgery. The
vein rings were suspended in organ bath chambers for isometric recording of tension. AVP (331029 mol/L) enhanced the
contractions elicited by electrical field stimulation at 1, 2, and 4 Hz (by 80%, 70%, and 60%, respectively) and produced
a leftward shift of the concentration-response curve to norepinephrine (half-maximal effective concentration decreased
from 6.8731027 to 1.0431027 mol/L; P,.05). The V1 vasopressin receptor antagonist d(CH2)5Tyr(Me)AVP (10
26 mol/L)
prevented the potentiation evoked by AVP. The selective V1 receptor agonist [Phe,
2 Orn8]-vasotocin (331029 mol/L)
induced potentiation of electrical stimulation–evoked responses, which was also inhibited in the presence of the V1
receptor antagonist (1026 mol/L). In contrast, the V2 receptor agonist desmopressin (10
29 to 1027 mol/L) did not modify
neurogenic responses, and the V2 receptor antagonist [d(CH2)5, D-Ile,
2 Ile,4 Arg8]-vasopressin (1028 to 1026 mol/L) did not
prevent the potentiation induced by AVP. The dihydropyridine calcium antagonist nifedipine (1026 mol/L) did not affect
the potentiating effect of AVP.
Conclusions—The results suggest that low concentrations of AVP facilitate sympathetic neurotransmission and potentiate
constrictor effects of norepinephrine in human saphenous veins. These effects appear to be mediated by V1 receptor
stimulation and are independent of calcium entry through dihydropyridine calcium channels. Thus, AVP may contribute
to vascular mechanisms involved in acute ischemic syndromes associated with venous grafts, particularly if the sympathetic
nervous system is activated. (Circulation. 1998;97:865-870.)
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A rginine vasopressin (AVP) is a neuropeptide that promotesreabsorption of water in renal tubular cells through V2
receptors and produces constriction of vascular smooth muscle
through V1 receptors.1–3 In human vessels, AVP causes pow-
erful V1 receptor–mediated constriction in isolated mesenter-
ic,4,5 cerebral,6,7 and renal8 arteries. This effect is endothelium
independent and due to direct stimulation of receptors located
on smooth muscle cells.5,9,10 Further studies of the physiological
effects of AVP have implicated a possible role of V2 receptors
in mediating vasodilation in some vascular beds.11–14
AVP may also modify the effects of other vasoactive
substances that are found in plasma or released from perivas-
cular nerve endings. Several studies in various animal species
have reported a significant augmentation by AVP of the
vasoconstricting action of catecholamines.15–17 However, in
other studies, AVP did not change the constrictor activity of
the peripheral sympathetic nervous system.18 In the human
forearm, AVP attenuates phenylephrine-induced vasoconstric-
tion,19 whereas recent experiments in human isolated mesen-
teric arteries show that AVP enhances adrenergic-mediated
responses.20 Currently, there is no information concerning the
modulating effects of AVP on human veins. A recent report
from our laboratory indicates that AVP exerts low contractile
effects on human saphenous veins compared with human
arteries,21 thus suggesting that these veins may have a low
population or sensitivity of receptor sites for this peptide.
However, this does not exclude the possibility that AVP could
importantly affect vascular tone if this peptide would facilitate
sympathetic neurotransmission or sensitize the vascular smooth
muscle to the effects of norepinephrine. This might have
important implications in our understanding of the detrimental
effects associated with acute ischemic syndromes after autolo-
gous grafts in the arterial circulation or coronary bypass
surgery.22–24 Accordingly, the objective of this investigation
was to determine whether low concentrations of AVP could
modify the constrictor responses to adrenergic stimulation of
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human saphenous veins. We also determined whether the
modulating effect of AVP on vascular responsiveness depends
on activation of V1 or V2 receptors.
Methods
Vein segments were taken from portions of human saphenous veins of
patients undergoing coronary artery bypass surgery (32 patients; 23
men and 9 women; age range, 52 to 71 years). The study was
approved by the ethical committee of our institution, and informed
consent was obtained from each patient before the study. During
surgical preparation of the saphenous vein, the dilation procedure was
avoided. The veins were immediately placed in chilled Krebs-
Henseleit solution, and rings 3 mm long were cut for isometric
recording of tension.
Two stainless steel L-shaped pins 200 mm in diameter were
introduced through the lumen of the vein ring. One pin was fixed to
the wall of the organ bath, and the other was connected to a
force-displacement transducer (Grass FT03). Changes in isometric
force were recorded on a Grass polygraph (model 7). Each vein ring
was set up in a 4-mL bath that contained modified Krebs-Henseleit
solution of the following millimolar composition: NaCl 115, KCl 4.6,
MgCl2 z 6H2O 1.2, CaCl2 2.5, NaHCO3 25, glucose 11.1, and
disodium EDTA 0.01. The solution was equilibrated with 95%
oxygen and 5% carbon dioxide to a pH of 7.3 to 7.4. Temperature was
held at 37°C. To establish the resting tension for maximal force
development, a series of preliminary experiments was performed on
vein rings of similar length and outer diameter that were exposed
repeatedly to 100 mmol/L KCl. Basal tension was increased gradually
until contractions were maximal. The optimal resting tension was 3 g.
The vein rings were allowed to attain a steady level of tension during
a 2- to 3-hour accommodation period before testing. Functional
integrity of the endothelium was confirmed routinely at the beginning
of the experiment by the presence or absence of relaxation induced by
acetylcholine (1027 to 1026 mol/L) or substance P (1029 mol/L) during
contraction obtained with norepinephrine (1027 to 331027 mol/L).
Electrical field stimulation was provided by a Grass S88 stimulator
via two platinum electrodes positioned on each side and parallel to the
axis of the vein ring. To assess the nature of the contractile responses
and to avoid direct stimulation of the smooth muscle, frequency-
response relationships were determined on a group of veins in the
presence and absence of 1026 mol/L tetrodotoxin following previously
described procedures.25 In summary, the protocol was designed to find
the optimal stimulation parameters (15 V, 0.2-ms duration) causing a
contractile response that was completely eliminated by 1026 mol/L
tetrodotoxin. Frequency-response relationships were determined with
15-second trains of pulses at 1, 2, and 4 Hz. A period of 10 minutes
was allowed between stimulations. The preparations were allowed to
equilibrate for at least 10 minutes before they were incubated with
tetrodotoxin (1026 mol/L) or prazosin (1026 mol/L). After 10 to 15
minutes of incubation with the antagonist, a second set of stimulations
was performed. In each experiment, a second frequency-response
relationship in untreated vein rings was run in parallel.
To study the effects of AVP on electrical field stimulation–induced
responses, frequency-response relationships were determined in a
separate group of experiments. After an initial set of stimulations, the
vein rings were consecutively incubated with increasing concentra-
tions of AVP (10210 to 331029 mol/L) for 10 minutes before another
set of stimulations was given. As a control, four consecutive sets of
stimulations were given to a group of untreated vein rings at identical
intervals. Less than 10% variability in the magnitude of electrical field
stimulation–induced contractions was observed for a given ring during
four consecutive sets of control stimulations.
In another series of experiments, after a first frequency-response
relationship was obtained, the preparations were incubated with either
the V1 receptor antagonist d(CH2)5Tyr(Me)AVP (1026 mol/L), the V1
receptor antagonist (1028 to 1026 mol/L) plus AVP (331029 mol/L),
the selective V1 receptor agonist [Phe,2 Orn8]-vasotocin (10210 to
331029 mol/L), the V1 receptor antagonist (1026 mol/L) plus the V1
receptor agonist (331029 mol/L), the V2 vasopressin agonist desmo-
pressin (1029 to 1027 mol/L), the V2 receptor antagonist [d(CH2)5,
D-Ile,2 Ile,4 Arg8]-vasopressin (1028 to 1026 mol/L) plus AVP (331029
mol/L), or the reuptake blocker cocaine (1026 mol/L) plus AVP
(331029 mol/L). After 10 to 15 minutes of incubation with the
corresponding drug, a second set of stimulations was then performed.
In each group of experiments, stimulations without any treatment
were run in parallel.
Concentration-response curves for norepinephrine (1029 to 331025
mol/L) and KCl (5 to 120 mmol/L) were determined in a cumulative
manner. Control (in the absence of AVP) and experimental (in the
presence of AVP) data were obtained from separate vascular prepara-
tions. Another group of vein rings was incubated with the V1 receptor
antagonist (1026 mol/L) plus AVP (331029 mol/L) before exposure to
norepinephrine or KCl.
In another group of experiments, electrical field stimulation was
carried out under control conditions followed by a second set of
stimulations in the presence of nifedipine (1026 mol/L); then a third
set of stimulations was performed in the presence of nifedipine plus
AVP (331029 mol/L). Frequency-response curves without any treat-
ment were run in parallel. In another group of veins, norepinephrine
(1029 to 331025 mol/L) was applied in the presence of either
nifedipine (1026 mol/L) or nifedipine plus AVP (331029 mol/L), and
the data were compared with those obtained from untreated (control)
segments.
Drugs
The following drugs were used: tetrodotoxin, nifedipine, prazosin,
norepinephrine hydrochloride, acetylcholine chloride, AVP acetate
salt, [(1-(b-mercapto-b,b-cyclopentamethylenepropionic acid)-2-
(O-methyl)-tyrosine, 8-arginine) vasopressin] [d(CH2)5Tyr(Me)AVP],
deamino-8-D-arginine vasopressin (desmopressin), substance P acetate
salt (Sigma Chemical Co), [Phe,2 Orn8]-vasotocin, [d(CH2)5, D-Ile,2
Ile,4 Arg8]-vasopressin (Peninsula Laboratories Europe), and cocaine
chlorhydrate (Abello´). All drugs were dissolved in Krebs-Henseleit
solution except nifedipine, which was dissolved initially in ethanol and
further diluted in Krebs solution to the proper final concentration.
Drugs were added to the organ bath in volumes of ,70 mL. Stock
solutions of the drugs were freshly prepared every day and kept on ice
throughout the experiment.
Data Analysis
All values are expressed as mean6SE. Contractions are reported in
absolute tension (grams) or as a percentage of response to KCl
(100 mmol/L). EC50 values (concentrations of agonist producing
half-maximal contraction) were determined from individual concen-
tration-response curves by nonlinear regression analysis, and from
these values the geometric means were calculated. The EC50 values
were compared by an unpaired t test and an ANOVA with Scheffe´’s
test as post hoc test. The number of rings taken from each patient
varied from 8 to 16. Concentration-response curves of the tested
agonists or frequency-response relationships were performed in the
presence and absence of either AVP or the antagonists in rings
obtained from the same patient; the responses obtained in each patient
were averaged to yield a single value. Therefore, all number (n) values
are presented as the number of patients from whom the blood vessel
were obtained. For electrical stimulation experiments in which the
same veins were stimulated in the absence and presence of AVP, a
paired t test was used. Statistical significance was accepted at P,.05.
Results
Effects of AVP
AVP (1029 to 1026 mol/L) caused concentration-dependent
contractions with an EC50 of 1.531028 mol/L, which is similar
to values previously reported by us.21 The presence of the V1
antagonist d(CH2)5Tyr(Me)AVP in the organ bath displaced
the control curve to AVP to the right in a parallel manner
(EC50, 2.831027 mol/L), but differences in the maximal
tensions developed were not significant (23.163.3%, n58,
versus 23.363.8%, n55, of response to 100 mmol/L KCl).
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The a1-adrenoceptor blocker prazosin (1026 mol/L) did not
affect the concentration-response curve to AVP (EC50,
1.131028 mol/L; maximal response, 22.463.1% of KCl
contraction).
Effects of Electrical Stimulation
Electrical stimulation induced frequency-dependent increases
in tension in all the experiments that were abolished by
tetrodotoxin (1026 mol/L) and prazosin (1026 mol/L), thus
indicating that the effect was due to the release of norepineph-
rine from perivascular adrenergic nerves acting on
a1-adrenoceptors.
AVP (10211 to 3310211 mol/L) did not change the contrac-
tions to electrical stimulation at the frequencies used (1, 2, and
4 Hz). At higher concentrations (10210 to 331029 mol/L),
AVP caused potentiation of the electrically evoked responses
(Fig 1A and 1B). The V1 receptor antagonist
d(CH2)5Tyr(Me)AVP (1026 mol/L) did not change control
responses to electrical field stimulation but prevented the
amplifying effect of AVP at all the frequencies used (Fig 1C).
The selective V1 receptor agonist [Phe2, Orn8]-vasotocin
induced a potentiation of electrical stimulation–evoked re-
sponses of a magnitude similar to that observed in the presence
of AVP. This potentiation was also inhibited in the presence of
the V1 receptor antagonist d(CH2)5Tyr(Me)AVP (1026 mol/L)
(Fig 2A).
To determine whether V2 receptors are involved in the
effects of AVP on field electrical stimulation, frequency-
response relationships were obtained in the absence and in the
presence of the V2 receptor antagonist [d(CH2)5, D-Ile2, Ile4,
Arg8]-vasopressin. Fig 2B shows that the potentiation induced
by AVP was not modified in the presence of 1028 to 1026
mol/L of the V2 receptor antagonist. In addition, the selective
V2 receptor agonist desmopressin (1029 to 1027 mol/L) did not
modify the control frequency-response relationship (P..05,
n56) (results not shown).
Blockade of neuronal catecholamines reuptake by cocaine
(1026 mol/L) had no effect on the potentiating effects of AVP
on electrical field stimulation (Fig 2C).
Figure 1. A, Tracings of contractile responses to field electrical
stimulation (2 Hz) of isolated human saphenous veins under
control conditions and after incubation with various concentra-
tions of arginine vasopressin (AVP; 10210 to 331029 mol/L). B,
Average contractions to electrical field stimulation in the
absence and in the presence of increasing concentrations of
AVP (10210 to 331029 mol/L). C, Effects of 331029 mol/L AVP
on frequency-dependent contractile responses to electrical field
stimulation in the absence and in the presence of V1 receptor
antagonist d(CH2)5Tyr(Me)AVP (1026 mol/L). *Significant differ-
ences from control value, P,.05.
Figure 2. A, Contractile response to electrical field stimulation
(2 Hz) in the absence and in the presence of increasing concen-
trations of the V1 receptor agonist [Phe,2 Orn8]-vasotocin (10210
to 3x1029 mol/L). The presence of the V1 receptor antagonist
d(CH2)5Tyr(Me)AVP (1026 mol/L) abolished the augmentation of
the contraction to electrical field stimulation by the V1 receptor
agonist. B, Contractile responses to electrical field stimulation in
the absence and in the presence of increasing concentrations of
the V2 receptor antagonist [d(CH2)5, D-Ile,2 Ile,4 Arg8]-vasopressin
(1028 to 1026 mol/L). The potentiation induced by AVP (331029
mol/L) was not affected in the presence of the V2 receptor an-
tagonist. C, Frequency-response relationship in the absence
and presence of cocaine (1026 mol/L) or cocaine together with
AVP (331029 mol/L). Values are mean6SEM. *Significant differ-
ences (P,.05) from control value.
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Effect of AVP on Norepinephrine- and
KCl-Induced Contraction
AVP potentiated norepinephrine-induced contractions in a
concentration-dependent manner (Fig 3A). The norepineph-
rine EC50 values and maximal responses in the presence and
absence of AVP are shown in the Table. The V1 receptor
antagonist d(CH2)5Tyr(Me)AVP produced a parallel, rightward
shift of the potentiating effects of 331029 mol/L AVP on the
norepinephrine concentration-response curve. At 1026 mol/L,
the V1 inhibitor brought the EC50 to values similar to those
obtained in the norepinephrine control curve. In contrast, AVP
(10210 to 331029 mol/L) did not affect the concentration-
response curve to KCl (10 to 120 mmol/L) (Fig 3B).
AVP and Calcium
The dihydropyridine calcium antagonist nifedipine (1026
mol/L) did not significantly change the contraction induced by
AVP and electrical field stimulation (Fig 4A and 4B). The
presence of nifedipine diminished maximal responses to nor-
epinephrine, but EC50 was not altered (6.631027 versus
5.231027 mol/L) (Fig 4C). In addition, the enhancement of
the contractile responses to electrical field stimulation and
norepinephrine by AVP was identical to that observed in the
absence of nifedipine (Fig 4B and 4C). However, KCl-
induced contractions were significantly reduced in the pres-
ence of nifedipine (1026 mol/L) (Fig 4D).
Discussion
The results of this study demonstrate that in the human
saphenous vein, low concentrations of AVP enhance the
Figure 4. A, Concentration-response curves to AVP in the
absence (F, n57) and in the presence (E, n56) of nifedipine
(1026 mol/L). B, Frequency-response relationship under control
conditions (solid bars, n55) and in the presence of nifedipine
(1026 mol/L, open bars, n55) or nifedipine plus AVP (331029
mol/L, hatched bars, n55). C, Concentration-response curves to
norepinephrine in the absence (F, n56) and in the presence of
either nifedipine (1026 mol/L, E, n58) or nifedipine together with
AVP (331029 mol/L, n, n56). D, Concentration-response curves
to KCl in the absence (F, n57) and in the presence of nifedipine
(1026 mol/L, E, n57). Values are mean6SEM. *Significant differ-
ences from control values, P,.05.
EC50 Values and Maximal Contractions to Norepinephrine Alone (Control) and in the
Presence of Either AVP or the V1 Receptor Antagonist Together With AVP
Norepinephrine
EC50, mol/L
(95% Confidence Interval)
Maximal Responses,
%6SEM
Control (n56) 6.8731027 135.266.1
(6.653102727.0931027)
With AVP
3310210 mol/L (n54) 2.7931027* 126.969.1
(2.623102722.9631027)
1029 mol/L (n54) 2.6431027* 152.964.1
(1.183102724.131027)
331029 mol/L (n54) 1.0431027* 140.367.9
(0.533102721.4731027)
With V1 receptor antagonist 6.0831027 133.9 66.2
(1026 mol/L)1AVP (331029 mol/L) (n54) (5.813102726.1931027)
AVP indicates arginine vasopressin. Values are mean6SEM. Maximal contraction is expressed as a percentage of
response to 100 mmol/L KCl.
*P,.05 vs control rings.
Figure 3. A, Contractile effects of norepinephrine in the
absence (F, n56) and in the presence of arginine vasopressin
(AVP) (n, 1029 mol/L, n54; ▫, 331029 mol/L, n54) and in the
presence of the V1 receptor antagonist (1026 mol/L) together
with AVP (331029 mol/L, , n54). B, Concentration-response
curves to KCl in the absence (F, n59) and in the presence (E,
n57) of 331029 mol/L AVP. Values are mean6SEM.
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contractile effects of electrical field stimulation and norepi-
nephrine. The potentiating effects occur at AVP concentra-
tions substantially lower than those required to produce a clear
direct contractile response. In a previous work,21 we found that
contractions of human saphenous veins in response to AVP are
relatively low compared with human arteries, indicating that
these veins may have a low population or sensitivity of receptor
sites for this peptide. However, an interesting finding of the
present study is that the low responsiveness of the saphenous
vein coincides with a high sensitivity to the modulating effects
of AVP on adrenergic-mediated responses. Thus, it appears
that the indirect (potentiating) effects of AVP on human
saphenous vein may act synergistically with the effects of
adrenergic stimulation.
Previous studies have suggested the existence of V2 receptors
in some vascular beds that could mediate vasodilatation.
Administration of either V2 receptor agonists or vasopressin
during V1 receptor blockade increased blood flow in some
vascular beds and decreased peripheral resistance in both
humans and dogs.11–13 In the human saphenous vein, both AVP
and the V2 receptor agonist desmopressin cause relaxation that
seems largely dependent on the release of dilating prostaglan-
dins.21 Therefore, we examined the potential role of V2
receptor stimulation in the enhancing effects of AVP. The
results do not support the intervention of V2 receptors in these
responses. First, the selective V2 receptor agonist desmopressin
did not modify responses to electrical field stimulation. On the
other hand, the V2 receptor antagonist [d(CH2)5, D-Ile,2 Ile,4
Arg8]-vasopressin did not affect the potentiation induced by
AVP. In contrast, the selective V1 receptor antagonist
d(CH2)5Tyr(Me)AVP inhibited the amplifying effects of AVP
on electrical field stimulation and norepinephrine-induced
contractions in a concentration-dependent manner. In addi-
tion, the selective V1 receptor agonist [Phe,2 Orn8]-vasotocin
induced potentiating effects similar to those observed in the
presence of AVP. Therefore, the results exclude a role for V2
receptors in the potentiating effects of AVP and are consistent
with the hypothesis that V1 receptor stimulation in the absence
of direct contraction is followed by enhancement of responses
to both endogenous and exogenous norepinephrine.
It might be conceived that the effects of AVP on electrical
field stimulation contractions could involve an effect on
adrenergic nerves, leading to release of norepinephrine, or
alternatively AVP could act with norepinephrine at postjunc-
tional receptor sites. Because norepinephrine release was not
measured in this study, a contribution of presynaptic facilitat-
ing effects cannot be excluded. The fact that the concentra-
tion-response curve to AVP was not modified by prazosin, an
a1-adrenoceptor blocker, suggests that the action of this
peptide does not involve release of norepinephrine. The
possibility that AVP could block the reuptake of norepineph-
rine and therefore enhance the contractile responses is unlikely
because the potentiating effects were still evident in the
presence of cocaine. Alternatively, AVP-induced potentiation
could be due to alterations at the receptor level, leading to an
increased affinity of norepinephrine for its receptor. This may
be a likely explanation because AVP increased the contractions
to exogenously applied norepinephrine. Thus, our data are
consistent with the suggestion that potentiation of the effects of
nerve stimulation by AVP corresponds to a postsynaptic
enhancement of the action of norepinephrine.
We also considered the possibility that stimulation of V1
receptors may facilitate calcium entry through dihydropyridine
calcium channels. Our results show that nifedipine did not
affect the direct contractions of AVP or prevent the potenti-
ating action of AVP on norepinephrine- and electrical field
stimulation–induced contractions. This indicates that influx of
extracellular calcium through dihydropyridine-sensitive cal-
cium channels does not importantly contribute to the direct
contractile effects of AVP or participate in the potentiating
effect of AVP on adrenergic contractions. In line with that
interpretation, our results show that AVP did not affect the
concentration-response curve to KCl, an agent that induces
contraction by facilitating calcium entry through voltage-
dependent calcium channels. Other mechanisms of calcium
handling such as an increase in inositol phosphate metabolism
and/or increase calcium release from intracellular reser-
voirs1,26,27 may be involved in the potentiating effects of AVP.
In contrast, in human mesenteric arteries, AVP brings about a
facilitation of extracellular Ca21 entry by KCl through voltage-
dependent calcium channels.20 The precise explanation for
such tissue specificity is not known, but it may be due to
differences in distribution and pharmacological properties of V1
vascular receptors between mesenteric arteries and saphenous
veins.
In contrast to the present results, Hilgers et al18 did not find
any effect of AVP on sympathetic transmission in an in vitro
perfused rat hind limb preparation. A common finding in the
vascular effects of this peptide is the heterogeneity of respon-
siveness depending on regional and species differences28,29 and
may be due to different populations or sensitivity of receptor
sites for AVP.6,8,30 In addition, Hilgers et al18 used only one
concentration of AVP (0.3 nmol/L), which probably was
insufficient to modulate neurogenic responses. Because the
present findings show that the potentiating effects of AVP are
concentration dependent, it is conceivable that differences
between the concentrations of AVP used may also account for
the discrepant findings of our study and those of Hilgers et al.18
Some of the present observations may be of clinical signif-
icance. Several reports indicate that large arteries and veins
from various animal species may synthesize and store an AVP
immunoreactive material that appears identical to authentic
AVP, thus suggesting that the vascular peptide is of local rather
than neurohypophysial origin.31,32 This raises the possibility
that locally released AVP may reach concentrations high
enough to act synergistically with the adrenergic neurotrans-
mitter. The concentration of AVP in this study may be lower
than those expected to occur in response to hypotension,
dehydration, and exercise and in some patients with hyperten-
sion or congestive heart failure.33–35 Consequently, the ampli-
fying effect of AVP on adrenergic-mediated constriction,
shown in the present experiments, may importantly contribute
to vascular mechanisms involved in acute ischemic syndromes
associated with venous grafts. The human saphenous vein can
undergo spasm, which is a clinically relevant problem, imme-
diately after autologous grafts in the arterial circulation or
coronary bypass surgery.22–24 In view of the specificity and
potency of the V1 antagonist d(CH2)5Tyr(Me)AVP, it seems
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appropriate to consider the use of V1 receptor antagonists in
circumstances in which AVP plasma concentrations are raised.
Furthermore, provided that V1 receptor blockade is present,
AVP induces marked dilatation of previously contracted hu-
man arteries5 and saphenous veins,21 probably because of the
release of vasodilatory prostaglandins from the vessel wall.
These findings could explain the reduction of vascular resis-
tance that has been observed after intravenous administration
of the V1 antagonist d(CH2)5Tyr(Me)AVP in patients with
hypertension or congestive heart failure in the presence of high
plasma AVP levels.34,36
In conclusion, the results of the present study demonstrate
that AVP, in addition to its direct vasoconstrictor effect,
strongly potentiates the contractions of human saphenous veins
to norepinephrine and stimulation of perivascular sympathetic
nerves. Both the direct and indirect effects of AVP appear to be
mediated by V1 receptor stimulation. The potentiation induced
by AVP is not related to activation of dihydropyridine-
sensitive calcium channels.
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